High levels of platelet inhibition with abciximab despite heightened platelet activation and aggregation during thrombolysis for acute myocardial infarction: Results from TIMI (thrombolysis in myocardial infarction) 14
Immunoglobulin Fab Fragments
Platelet Aggregation Inhibitors
Tissue Plasminogen Activator
Platelet activation and aggregation are heightened in the setting of thrombolysis for AMI. Despite this enhanced level of platelet activation, abciximab, combined with a reduced-dose thrombolytic, inhibited platelet aggregation similarly to the level reported in elective settings.